Error in Open Access Status

June 1, 2026
0 min

Jama Cardiology

Overview

The article titled 'Semaglutide and Hospitalizations in Patients With Obesity and Established Cardiovascular Disease' has been corrected to reflect its open access status as CC-BY-NC-ND. This correction was made online following the original publication on December 23, 2025.

Background

The management of obesity in patients with established cardiovascular disease (CVD) is critical, as obesity significantly increases cardiovascular risk. Recent guidelines from the American College of Cardiology emphasize the importance of pharmacologic interventions, such as GLP-1 receptor agonists like semaglutide, in optimizing cardiovascular health. Understanding the implications of these treatments on hospitalization rates is essential for improving patient outcomes.

Data Highlights

No numerical data or trial results are provided in the source material.

Key Findings

The open access license for the article has been corrected to CC-BY-NC-ND.
The original investigation was published on December 23, 2025.
This correction was made online after the initial publication.
Semaglutide is a GLP-1 receptor agonist relevant to obesity management in patients with CVD.
Recent guidelines support the use of modern anti-obesity pharmacotherapies as first-line treatments.

Clinical Implications

Healthcare professionals should be aware of the updated open access status of the article for broader accessibility. The findings related to semaglutide and its role in managing obesity and cardiovascular health are pertinent for clinical practice.

Conclusion

The correction of the open access license enhances the availability of important research findings on semaglutide and its implications for patients with obesity and CVD.